Furthermore, consistent with the poor overall survival in NLRC4lo CRC tumors, compared with early clinical stages I–II (n = 44) and locally advanced stage III cancer (n = 37), a gradual loss of tumor NLRC4 protein expression was further observed in metastatic stage IV cancer (n = 23) (stage I–II vs. IV, P = 0.0082) in our Bergonié cohort (Figure 1A). Here, NLRC4 is linked to cancer.